How much revenue does Youcare Pharmaceutical Group make?

Youcare Pharmaceutical Group reported 3.78 billion CNY in revenue for fiscal year 2024, down 9.9% from 4.20 billion CNY in fiscal year 2023. In Q2 2025 revenue was 590.00 million CNY.

What is Youcare Pharmaceutical Group's largest business segment?

Cardiovascular, with 1.06 billion CNY or 44% of segment revenue in fiscal year 2025. Next: Anti-Infective (24%) and Active Pharmaceutical Ingredient (9%).

Where does Youcare Pharmaceutical Group make most of its revenue?

China: 97% of revenue by region in fiscal year 2025, followed by Overseas (3%).

What companies are similar to Youcare Pharmaceutical Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS), Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ), Hainan Haiyao Co., Ltd. (000566.SZ), Beijing SL Pharmaceutical Co., Ltd. (002038.SZ).

Youcare Pharmaceutical Group Co., Ltd. (688658.SS) Stock

About Youcare Pharmaceutical Group Co., Ltd.

Youcare Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It offers drugs in various forms, such as injection, lyophilized powder injection, pills, tablets, capsules, ointments, creams, granules, etc. The company provides drugs in various categories, including covering cardio-cerebrovascular, antivirals, central ...

At a glance

Youcare Pharmaceutical Group reported revenue of 3.78 billion CNY for fiscal year 2024, down 9.9% from fiscal year 2023, and net income of 123.72 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 590.00 million CNY, down 39.9% from a year before. Its largest business segment, Cardiovascular, brought in 44% of segment revenue in fiscal year 2025; China was the largest region with 97%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.